Figure 3.
The therapeutic efficacy of BO-1978 against EGFR wild-type NSCLC cells. (A) Suppression of H460 xenografts by BO-1978. H460 cells (3 × 106) were subcutaneously implanted in nude mice. When the tumor size reached approximately 100 mm3, the tumor-bearing mice were intravenously treated with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), or cisplatin (6 mg/kg, three times every 4 days). The tumor size and body weight were measured at the times indicated. (B) Suppression of orthotopically implanted CL1-5/GFP-Luciferase cells by BO-1978. CL1-5/GFP-Luciferase cells (5 × 106) were orthotopically implanted in the lungs of nude mice. The tumor-bearing mice were treated with vehicle, BO-1978, or cisplatin, as described above. (Left) The representative images of mice implanted with CL1-5/GFP-Luciferase cells and treated with drugs. (Middle and right) The quantitative signals of luciferase (p/s per cm2 per sr) and the relative body weights of mice treated with vehicle, BO-1978, or cisplatin, respectively. p, photon; sr, steradian. (C) No tumor formation in the lungs of orthotopically implanted mice treated with BO-1978. On day 19, the lungs were harvested from mice treated with vehicle, BO-1978, or cisplatin; histopathologically sectioned; and stained with hematoxylin and eosin.